Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings

Key Points

• Leerink Partners has revised its FY2025 earnings estimates for Ionis Pharmaceuticals from ($2.78) to ($2.64) per share, indicating a more optimistic outlook.
• Ionis recently reported a strong quarterly performance with $452 million in revenue, significantly surpassing analysts' expectations of $270.9 million, and showing a 100.9% year-over-year increase.
• Analyst ratings for Ionis Pharmaceuticals are largely positive, with the average rating at "Moderate Buy" and a consensus price target of $72.71.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at Leerink Partnrs raised their FY2025 earnings estimates for Ionis Pharmaceuticals in a report released on Tuesday, September 23rd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($2.64) per share for the year, up from their previous forecast of ($2.78). The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals' Q4 2025 earnings at ($1.30) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($1.15) EPS and FY2028 earnings at ($0.24) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.51. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The business had revenue of $452.00 million during the quarter, compared to the consensus estimate of $270.90 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The business's revenue for the quarter was up 100.9% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Other equities analysts also recently issued reports about the company. The Goldman Sachs Group raised their price target on Ionis Pharmaceuticals from $40.00 to $45.00 and gave the company a "sell" rating in a report on Wednesday, September 3rd. Raymond James Financial set a $75.00 price objective on shares of Ionis Pharmaceuticals and gave the company a "strong-buy" rating in a research report on Monday. Bank of America lifted their target price on shares of Ionis Pharmaceuticals from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Finally, BMO Capital Markets upgraded shares of Ionis Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the company from $40.00 to $70.00 in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $72.71.

Ionis Pharmaceuticals Stock Down 1.5%

IONS stock opened at $62.97 on Friday. The business has a 50 day moving average of $49.35 and a 200 day moving average of $39.21. The firm has a market cap of $10.04 billion, a PE ratio of -34.22 and a beta of 0.28. Ionis Pharmaceuticals has a twelve month low of $23.95 and a twelve month high of $64.71. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99.

Insider Activity

In other news, EVP C Frank Bennett sold 33,909 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $60.62, for a total transaction of $2,055,563.58. Following the transaction, the executive vice president directly owned 101,570 shares of the company's stock, valued at $6,157,173.40. This represents a 25.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Patrick R. O'neil sold 76,850 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $60.97, for a total value of $4,685,544.50. Following the completion of the sale, the executive vice president directly owned 5,655 shares of the company's stock, valued at $344,785.35. The trade was a 93.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 492,841 shares of company stock valued at $28,595,925 over the last three months. Corporate insiders own 2.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IONS. Exome Asset Management LLC grew its position in shares of Ionis Pharmaceuticals by 121.0% during the 1st quarter. Exome Asset Management LLC now owns 135,616 shares of the company's stock valued at $4,092,000 after acquiring an additional 74,249 shares during the period. GAMMA Investing LLC grew its holdings in Ionis Pharmaceuticals by 3,786.5% during the first quarter. GAMMA Investing LLC now owns 28,993 shares of the company's stock valued at $961,000 after purchasing an additional 28,247 shares during the period. Raymond James Financial Inc. increased its position in Ionis Pharmaceuticals by 40.8% in the first quarter. Raymond James Financial Inc. now owns 148,690 shares of the company's stock worth $4,486,000 after buying an additional 43,071 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Ionis Pharmaceuticals by 4.8% in the first quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock worth $301,000 after buying an additional 458 shares during the period. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $3,747,000. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.